German PMS Trial (AWB) to Evaluate Therapy in Reflux Disease and NSAR-Symptoms
Launched by ASTRAZENECA · Dec 3, 2007
Trial Information
Current as of June 06, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with GERD, or NSAID related ulcers, who need treatment with esomeprazole.
- Exclusion Criteria:
- • Limitations; possible risks; warnings; contraindications mentioned in the SPC.
About Astrazeneca
AstraZeneca is a global biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative medicines across various therapeutic areas, including oncology, cardiovascular, respiratory, and autoimmune diseases. With a strong commitment to scientific research and patient-centric solutions, AstraZeneca leverages cutting-edge technology and a robust pipeline to address unmet medical needs. The company collaborates with healthcare professionals, academic institutions, and other organizations to advance clinical trials and deliver transformative therapies, aiming to improve health outcomes and enhance the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Kai Richter, MD
Study Director
AstraZeneca Medical Department
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials